Skip to main content

Table 2 A comparison of clinical characteristics the DR-TB cases reviewed by the national DR-TB consilium with those not reviewed

From: Multidisciplinary management of difficult-to-treat drug resistant tuberculosis: a review of cases presented to the national consilium in Uganda

Clinical characteristic Review status
Not reviewed n = 933 95% CI Reviewed n = 189 95% CI
Body mass index, kg/m2 n = 473
 < 18.5 195 (55.9) 50.6, 61.0 81 (65.3) 56.5, 73.2
18.5–24.9 142 (40.7) 35.6, 45.9 39 (31.5) 23.8, 40.2
25.0–29.9 12 (3.4) 2.0, 6.0 4 (3.2) 1.2, 8.4
History of TB treatment
Yes 556 (59.6) 56.4, 62.7 107 (56.6) 49.4, 63.5
No 377 (40.4) 37.3, 43.6 82 (43.4) 36.5, 50.6
HIV Status     
Positive 564 (60.5) 57.3, 63.5 102 (54) 46.8, 61.0
Negative 369 (39.5) 36.5, 42.7 87 (46) 39.0, 53.2
Cotrimoxazole use, n = 603
Yes 491 (97) 95.1, 98.2 96 (99) 92.9, 99.9
No 15 (3) 1.8, 4.9 1 (1) 0.1, 7.1
ART use, n = 655
Yes 521 (94) 91.7, 95.7 101 (100) -
No 33 (6) 4.3, 8.3 0 (0) -
History of ART default, n = 491
Yes 60 (14.7) 11.6, 18.5 26 (31) 21.9, 41.8
No 347 (85.3) 81.5, 88.4 58 (69) 58.2, 78.1
Diabetes, n = 151     
Yes 36 (33) 24.8, 42.5 12 (28.6) 16.7, 44.4
No 73 (67) 57.5, 75.2 30 (71.4) 55.6, 83.3
Hypertension, n = 479
Yes 19 (4.6) 2.9, 7.0 5 (8.1) 3.3, 18.2
No 398 (95.4) 93.0, 97.1 57 (91.9) 81.8, 96.7
Systolic blood pressure, n = 479
 < 90 32 (7.7) 5.5, 10.7 10 (16.1) 8.8, 28.7
90–140 375 (89.9) 86.6, 92.5 48 (77.4) 65.1, 86.3
 > 140 10 (2.4) 1.3, 4.4 4 (6.5) 2.4, 16.2
Diastolic blood pressure, n = 479
 < 60 41 (9.8) 7.3, 13.1 10 (16.1) 8.8, 27.7
60–90 362 (86.8) 83.2, 89.7 51 (82.3) 70.5, 90.0
 > 90 14 (3.4) 2.0, 5.6 1 (1.6) 0.2, 11.0
Cancer
No 919 (98.5) 97.5, 99.1 186 (98.4) 95.2, 99.5
Yes 14 (1.5) 0.9, 2.5 3 (1.6) 0.5, 4.8
Elevated creatinine, n = 934
Yes 231 (29.4) 26.3, 32.6 48 (32.7) 25.5, 40.7
No 556 (70.6) 67.4, 73.7 99 (67.3) 59.3, 74.5
Hepatic injury§, n = 928
Yes 639 (82.8) 79.9, 85.3 141 (90.4) 84.6, 94.1
No 133 (17.2) 14.7, 20.1 15 (9.6) 5.9, 15.4
Hearing impairment, n = 803
Normal Hearing 351 (54.5) 50.6, 58.3 93 (58.5) 50.6, 65.9
Low Frequency 113 (17.5) 14.8, 20.7 24 (15.1) 10.3, 21.6
High Frequency 180 (28) 24.6, 31.6 42 (26.4) 20.1, 33.9
Distribution of hearing loss, n = 348
Bilateral hearing loss 233 (80.9) 75.9, 85.1 55 (91.7) 81.2, 96.6
Unilateral hearing loss 55 (19.1) 14.9, 24.1 5 (8.3) 3.4, 18.8
Grade of hearing loss, n = 314
Mild 145 (55.3) 49.2, 61.3 20 (38.5) 26.1, 52.6
Moderate 65 (24.8) 19.9, 30.4 18 (34.6) 22.8, 48.7
Severe 34 (13) 9.4, 17.6 9 (17.3) 9.1, 30.4
Profound 18 (6.9) 4.4, 10.7 5 (9.6) 4.0, 21.5
Psychiatric symptoms
Yes 49 (5.3) 4.0, 6.9 20 (10.6) 6.9, 15.9
No 884 (94.7) 93.1, 96.0 169 (89.4) 84.1, 93.1
Resistance to SLDs
Yes 4 (0.4) 0.1, 1.1 9 (4.8) 2.5, 8.9
No 929 (99.6) 98.9, 99.8 180 (95.2) 91.1, 97.5
Previous exposure to SLDS
Yes 17 (1.8) 1.1, 2.9 13 (6.9) 4.0, 11.5
No 916 (98.2) 97.1, 98.9 176 (93.1) 88.5, 96.0
  1. SLDs–second-line drugs,TB–tuberculosis, DR-TB–drug resistant TB, ART–antiretroviral therapy, SLDs–second-line drugs, defined as creatinine level of > 106.1 µmol per litre (µm/l) [23], § defined as elevation in any of total bilirubin, aspartate aminotransferase, gamma-glutamyl transferase, alanine aminotransferase and alkaline phosphatase at the respective cut offs of: > 2.5 mg/dl, > 34.8 units per litre (U/L), > 68.5 U/L, > 42.8 U/L and > 151 U/L [23]